Synthesis of Dibenzo[*def,p*]chrysene, Its Active Metabolites, and Their ¹³*C*-Labeled Analogues

Daiwang Xu,[†] Yazhen Duan,[†] Ian A. Blair,[‡] Trevor M. Penning,[§] and Ronald G. Harvey^{*,†}

Ben May Department for Cancer Research, University of Chicago, Chicago, Illinois 60637, and Centers for Cancer Pharmacology and Excellence in Environmental Toxicology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104


rharvey@huggins.bsd.uchicago.edu

Received December 19, 2007

ORGANIC LETTERS

2008 Vol. 10, No. 6 1059–1062

ABSTRACT



Dibenzo[*def,p*]chrysene (DBC) is a highly carcinogenic polycyclic aromatic hydrocarbon suspected to be involved in initiation of lung cancer in smokers. Efficient new syntheses of DBC, its active metabolites [DBC diol (1), DBC dione (2), DBC diol epoxide (3)], and their previously unknown ${}^{13}C_2$ -labeled analogues are reported. The ${}^{13}C_2$ -labeled analogues are required as standards for sensitive methods of analysis of their DNA adducts in human cells using stable isotope dilution liquid chromatography/tandem mass spectrometry.

Polycyclic aromatic hydrocarbons (PAHs) have recently been designated as human carcinogens by the WHO.¹ They are the most potent class of carcinogens commonly present in urban environments.^{2–4} PAHs are formed in combustion of organic matter,^{2–4} and significant levels are present in tobacco smoke,^{5–7} auto and diesel engine emissions,⁴ and charbroiled, smoked, and fried foods.⁴ Current evidence

indicates that PAHs are activated metabolically to reactive forms that attack DNA leading to mutations and cancer.

Three activation pathways have been proposed: the *diol* epoxide path (mediated by cytochrome P-450 enzymes),⁸ the radical-cation path (mediated by peroxidase),⁹ and the quinone path (mediated by aldo-keto reductase).¹⁰

Dibenzo[*def,p*]chrysene (DBC)¹¹ (Figure 1) is the most potent PAH carcinogen currently known.¹² It is present in cigarette smoke condensate¹³ and vehicle exhaust condensate.¹³ In connection with studies aimed at elucidation of

[†] University of Chicago.

[‡] Center for Cancer Pharmacology.

[§] Center for Excellence in Environmental Toxicology.

⁽¹⁾ Straif, K.; Boan, R.; Grosse, Y.; Secretan, B.; Ghissassi, F. E.; Cogliano, V. *Nat. Oncol.* **2005**, *6*, 931–932.

⁽²⁾ Harvey, R. G. Polycyclic Aromatic Hydrocarbons: Chemistry and Carcinogenicity; Cambridge University Press: Cambridge, U.K., 1991.

⁽³⁾ Harvey, R. G. *Polycyclic Aromatic Hydrocarbons*; Wiley-Interscience: New York, 1997; Chapter 1.

⁽⁴⁾ International Agency for Research on Cancer. *Polynuclear Aromatic Compounds, Part 1, Chemical, Environmental and Experimental Data;* Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Vol. 32; IARC: Lyon, France, 1983.

⁽⁵⁾ International Agency for Research on Cancer. *Tobacco Smoke and Involuntary Smoking*; Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Vol. 83; IARC: Lyon, France, 2004.

⁽⁶⁾ Pfiefer, G. P.; Denissenko, M. F.; Olivier, M.; Tretyakova, N.; Hecht, S.; Hainaut, P. *Oncogene* **2002**, *21*, 7435–7451.

⁽⁷⁾ World Health Organization. *Tobacco or Health: A Global Status Report*; WHO: Geneva, 1997; pp 10–48.

⁽⁸⁾ Harvey, R. G. Acc. Chem. Res. 1981, 14, 218–226. Conney, A. H. Cancer Res. 1082, 42, 4875–4910.

⁽⁹⁾ Cavalieri, E. L.; Rogan, R. E. Xenobiotica 1995, 25, 677-688.

⁽¹⁰⁾ Palackal, N. T.; Burczynski, M. E.; Harvey, R. G.; Penning, T. M. Biochemistry **2001**, 40, 10901–10910. Palackal, N. T.; Lee, S. H.; Harvey, R. G.; Blair, I. A.; Penning, T. M. J. Biol. Chem. **2002**, 277, 24799–24808. Penning, T. M.; Ohnishi, S. T.; Ohnishi, T.; Harvey, R. G. Chem. Res. Toxicol. **1996**, 9, 84–92.

⁽¹¹⁾ The name dibenzo[def,p]chrysene accords with IUPAC nomenclature rules and Chemical Abstracts, but the older name dibenzo[a,l]pyrene is still in use. See ref 3 for a condensed version of the rules of PAH nomenclature.





Figure 1. Structures of DBC and its active metabolites.

the role of DBC in human cancer, we required ${}^{13}C$ -labeled analogues of DBC and its active metabolites. These compounds were needed as standards for sensitive methods of stable isotope dilution liquid chromatography/tandem mass spectrometric analysis of the metabolites and DNA adducts of DBC.14,15

Although several syntheses of DBC16 and its active metabolites¹⁷ have been described, they involve multistep procedures that are not adaptable to synthesis of the ${}^{13}C$ labeled analogues. We now report convenient new syntheses of DBC and its active carcinogenic metabolites [DBC trans-11,12-dihydrodiol (1), DBC 11,12-dione (2), and the DBC anti- and syn-11,12-diol-13,14-epoxides (3)]. Also reported is synthesis of ¹³C-labeled DBC (¹³C-DBC) and the ¹³Clabeled analogues of 1-3 (¹³C-1, ¹³C-2, and ¹³C-3) by modification of this synthetic approach.

Synthesis of DBC. Pd-catalyzed Suzuki coupling of 2-bromophenylacetone (4) with 9-phenanthrylboronic acid (5) took place smoothly in the presence of Na_2CO_3 in DME to provide 2-(9-phenanthryl)phenylacetone (6) (82%) (Scheme 1). Attempted cyclodehydration of 6 to 9-methyl-benzo[g]chrysene (7a) failed to take place under the usual conditions for this type of reaction (20% MSA in CH₂Cl₂ at room temperature for 2 days).¹⁸ However, reaction took place under more vigorous conditions (50% MSA at 85-90 °C) to

Scheme 1. Synthesis of 9- and 10-Methylbenzo[g]chrysene



furnish a product whose ¹H NMR spectrum was more consistent with the structure of the 10-methyl isomer (7b) rather than 7a. Particularly revealing was the appearance of the methyl proton signal at δ 2.82, not shifted to higher field as expected for a methyl group in a crowded bay region. Also, the ¹H NMR spectrum of **7b** matched closely that reported for this compound.¹⁹ Evidently, migration of the methyl group occurred during or subsequent to cyclodehydration. Methyl migration in acid-catalyzed reactions of PAHs is well known.²⁰

A brief study of this reaction was undertaken to optimize conditions for synthesis of **7a**. Reaction of **6** with 20% MsOH at 90 °C for 3 days (Table 1) furnished equal amounts of 7a

time (h)	temp (°C)	$\mathrm{catalyst}^a$	7a (%)	7b (%)
48	\mathbf{rt}	20% MSA	0	0
72	90	20%MSA	20	20
2	90	50% MSA	0	70
48	90	Hf(OTf) ₄	0	10
20	\mathbf{rt}	$TiCl_4$	45	0
24	rt	$TiCl_4$	60	0
30	rt	$TiCl_4$	72	0
40	rt	$TiCl_4$	6	76
66	rt	$TiCl_4$	0	80

and **7b** (40%). Similar reaction of **6** with Hf(OTf)₄ as catalyst gave **7b** (10%) as the sole product. Reaction of **6** in the presence of TiCl₄ at room temp for times up to 30 h afforded mixtures of 7a and unreacted 6 with no detectable 7b. At

^{(12) (}a) Higginbotham, S.; RamaKrishna, N. S. V.; Johansson, S. I.; Rogan, E. G.; Cavalieri, E. L. Carcinogenesis 1993, 14, 875-878. (b) Cavalieri, E. L.; Higginbotham, S.; RamaKrishna, N. S. V.; Devanesan, P. D.; Todorovic, R.; Rogan, E. G.; Salmasi, S. Carcinogenesis 1991, 12, 1939-1944. (c) Masuda, Y.; Kagawa, R. Chem. Pharm. Bull. 1972, 20, 2736-2737. (d) Lacassagne, A.; Buu-Hoi, F.; Zajdela, F. A. Naturwissenschaften 1968. 55. 43.

⁽¹³⁾ Seidel, A.; Frank, H.; Behnke, A.; Schneider, D.; Jacob, J. Polycyclic Aromat. Compd. 2004, 24, 759-771

⁽¹⁴⁾ Ruan, Q.; Gelhaus, S.; Penning, T. M.; Harvey, R. G.; Blair, I. A. *Chem. Res. Toxicol.* **2007**, *20*, 424–431. (15) Ruan, Q.; Kim, H.; Jiang, H.; Penning, T. M.; Harvey, R. G.; Blair,

I. A. Rapid Commun. Mass Spectrom. 2006, 20, 1369-1380.

^{(16) (}a) Gill, H. S.; Kole, P. I.; Wiley, J. C.; Li, K. M.; Higginbotham, S.; Rogan, E. G.; Cavelieri, E. L. Carcinogenesis 1994, 15, 2455-2460. (b) Luch, A.; Glatt, H.; Platt, K. L.; Oesch, F.; Seidel, A. Carcinogenesis 1994, 15, 2507-2516. (c) Sharma, A. K.; Kumar, S.; Amin, S. J. Org. Chem. 2004, 69, 3979-3982.

^{(17) (}a) Zhang, J.-T.; Harvey, R. G. Tetrahedron 1999, 55, 625-636. (b) Krzeminski, J.; Lin, J.-M.; Amin, S.; Hecht, S. S. Chem. Res. Toxicol. **1994**, 7, 125–129.


⁽¹⁸⁾ Harvey, R. G.; Pataki, J.; Cortez, C.; DiRaddo, P.; Yang, C. J. Org. Chem. 1991, 56, 1210-1217.

⁽¹⁹⁾ Tinnemans, A. H. A.; Laarhoven, W. H. J. Am. Chem. Soc. 1974, 96, 4617-4622.

⁽²⁰⁾ Lindow, D. F.; Harvey, R. G. J. Am. Chem. Soc. 1971, 93, 3786-3787. Harvey, R. G.; Halonen, M. Can. J Chem. 1967, 45, 2630-2632.

30 h, the yield of **7a** was 72%, and 10% of **6** was recovered. With increasing times, the ratio of **6** continued to decrease, but the ratio of **7a** also began to decrease. At the same time, the ratio of **7b** increased, and by 66 h, it was the sole product. The most practical strategy for synthesis of **7a** was to quench reaction while a small amount of **6** remained and **7b** was not yet detectable (\sim 30 h), taking advantage of the fact that separation of **6** from **7a** is easy, while separation of **7a** from **7b** is difficult.

Transformation of **7a** to DBC was carried out via the sequence in Scheme 2. Bromination of **7a** with NBS gave




9-bromomethylbenzo[g]chrysene (**8a**), which was converted to 9-formylbenzo[g]chrysene (**8b**) by treatment with DMSO and NaHCO₃.²¹ Compound **8a** was somewhat unstable, but satisfactory yields of **8b** were obtainable by use of **8a** directly without purification. Wittig reaction of **8b** with methoxymethylenetriphenylphosphine afforded 9-(2-methoxy-vinyl)benzo[g]chrysene (**9**) as a mixture of the *E*- and *Z*-isomers (1:1 by NMR) (90%). Acid-catalyzed cyclization of **9**²² furnished **DBC** (75%).

Synthesis of ${}^{13}C_2$ –DBC. Because ${}^{13}C$ -labeled 2-bromophenylacetone (4) was unavailable, this synthesis was carried out by a modified procedure (Scheme 3). The starting compound, 2-(9-phenanthryl)benzaldehyde (10a), was prepared by Pd-catalyzed coupling of 2-formylphenyl-boronic acid with 9-bromophenanthrene. Wittig reaction of 10a with ${}^{13}C_2$ –EtPPh₃Br²³ and *t*-BuOK gave 11 as a mixture of *E*-and *Z*-isomers (8:1 by NMR analysis). Epoxidation of 11 with Oxone/acetone²⁴ gave 12 (87%), and it underwent rearrangement in the presence of Hf(OTf)₄ to furnish ${}^{13}C_2$ -2-(9-phenanthryl)phenylacetone (${}^{13}C_2$ -6) (74%). Cyclization of ${}^{13}C_2$ -6 with TiCl₄ by the procedure used for synthesis of 7a gave ${}^{13}C_2$ -7a, and this was converted to ${}^{13}C_2$ -DBC by the sequence for DBC.

Should a higher level of ${}^{13}C$ -labeling be desired, an additional ${}^{13}C$ -atom may be incorporated into ${}^{13}C$ -DBC via

(24) Hashimoto, N.; Kanda, A. Org. Process Res. Dev. 2002, 6, 405.



Wittig reaction of ${}^{13}C_2$ -**8b** with ${}^{13}C$ -labeled MeOCH=PPh₃ followed by acid-catalyzed cyclization to yield ${}^{13}C_3$ -**DBC**. A similar procedure was employed for introduction of ${}^{13}C$ in synthesis of ${}^{13}C_2$ -benzo[*a*]pyrene.²⁵

Synthesis of Active Metabolites of DBC (1-3) and their ¹³C₂-Labeled Analogues. The active metabolites of DBC were synthesized by modification of the method employed for synthesis of ¹³C₂-DBC (Scheme 4). The initial synthetic target was 10-hydroxy-DBC (19b), previously shown to be a synthetic precursor of all three metabolites (1-3).^{16,17}

Cross-coupling of 2-bromo-5-methoxybenzaldehyde with phenanthrene-9-boronic acid (5) provided 2-(9-phenanthryl)-5-methoxybenzaldehyde (10b) (62%). Wittig reaction of 10b with ethylenetriphenylphosphine (generated from reaction of EtPPh₃Br with *t*-BuOK) provided 13 (89%) as a mixture of *E*- and *Z*- isomers. Epoxidation of 13 with Oxone/acetone²⁴ furnished 14 (89%), which was converted to 2-(9-phenan-thryl)-5-methoxyphenylacetone (15) (70%) on stirring with Hf(OTf)₄ for 15 min at ambient temp.


TiCl₄-catalyzed cyclodehydration of **15** was monitored by TLC to determine the optimum time for minimization of rearrangement of 9-methyl-12-methoxybenzo[g]chrysene (**16**) to the 10-methyl isomer. The optimum time was only \sim 3 h (compared to \sim 30 h for analogous reaction of **6**). The increased rate of cyclization is likely a consequence of stabilization of the reaction intermediate by the electrondonating methoxy group. Bromination of **16** with NBS

⁽²¹⁾ Chen, H.; Luzy, J.-P.; Gresh, N.; Garbay, C. Eur. J. Chem. 2006, 2329–2335.

⁽²²⁾ Harvey, R. G.; Lim, K.; Dai, Q. J. Org. Chem. 2004, 69, 1372– 1373. Harvey, R. G.; Dai, Q.; Ran, C.; Penning, T. M. J. Org. Chem. 2004, 69, 2024–2032.

⁽²³⁾ ${}^{13}C_2$ -EtPh₃Br was prepared by addition of a solution of PPh₃ (4.77 g, 18.2 mmol) in toluene (8 mL) to ${}^{13}C_2$ -bromoethane (1 g, 9.1 mmol). The mixture was stirred at 120 °C for 2 days and then cooled to room temperature. The precipitate was filtered, washed with cold benzene (2 × 10 mL), and dried under vacuum to afford ${}^{13}C_2$ -EtPPh₃Br.

⁽²⁵⁾ Harvey, R. G.; Dai, Q.; Ran, C.; Lim, K.; Blair, I.; Penning, T. Polycyclic Aromat. Compd. 2005, 25, 371-391.



afforded 9-bromomethyl-12-methoxybenzo[g]chrysene which was converted to 9-formyl-12-methoxybenzo[g]chrysene (**17**)

by reaction with DMSO and NaHCO₃. Wittig reaction of **17** with methoxymethylenetriphenylphosphine provided **18** as a mixture of *E*- and *Z*-isomers that were used directly in the next step. Cyclization of **18** took place at 0 °C in the presence of MSA to furnish 12-methoxy-**DBC** (**19a**). Demethylation of **19a** by treatment with BBr₃ provided 12-hydroxy-**DBC** (**19b**) in good overall yield.

Syntheses of the active carcinogenic metabolites of **DBC** (1-3) from **19b** were carried out by the procedures described previously.^{16,17} Thus, oxidation of **19b** with Fremy's reagent provided **DBC** 11,12-dione (**2**), and reduction of **2** with NaBH₄ afforded DBC *trans*-11,12-dihydrodiol (**1**). The latter was, in turn, converted to the corresponding *anti*- and *syn*-11,12-diol-13,14-epoxide isomers (**3**) by the established procedures.¹⁷

The ${}^{13}C_2$ -labeled analogues of the active carcinogenic metabolites of **DBC** (${}^{13}C$ -**1**, ${}^{13}C$ -**2**, and ${}^{13}C$ -**3**) were synthesized from ${}^{13}C_2$ -**19b** by procedures analogous to those employed for synthesis of the corresponding unlabeled compounds. ${}^{13}C_2$ -**19b** was prepared from **10b** via Wittig reaction with ${}^{13}C_2$ -EtPPh₃Br and subsequent steps analogous to those described for synthesis of unlabeled **19b** from **10b** (Scheme 4).

Acknowledgment. This investigation was supported by NIH Grants (P01 CA 92537, R01 CA 039504, R01 ES 015857, and P30 ES 013508).

Supporting Information Available: Experimental details and spectroscopic data. This material is available free of charge via the Internet at http://pubs.acs.org.

OL7029323